Absci Corporation
ABSIHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Absci Corporation (ABSI) is listed under Biotechnology. At a $1.62B market cap, Absci Corporation ranks as a small-cap company within healthcare. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology.
Market Cap
$1.62B
Beta
2.28
P/E (TTM)
—
P/E (Fwd)
-14.00
EPS (TTM)
$-0.81
EPS (Fwd)
$-0.68
ROE
-57.7%
ROA
-34.1%
Cash
$201.1M
Total Debt
$3.8M
Free CF
-$50.6M
52W Change
110.0%
Annual Financials
Cash vs Debt
Where ABSI stands vs its 150-day and 200-day moving averages
As of the October 13, 2026 close, ABSI finished 36.58% above its 150-day moving average ($7.08) and 59.57% above its 200-day moving average ($6.06). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ABSI overbought or oversold?
At the October 13, 2026 close, ABSI's RSI(14) was 44.1, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $201.1M in cash and $3.8M in debt, ABSI maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$50.6M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -57.7% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $5.7M (2022) to $2.8M (2025), a 51% decline worth watching.
With a beta above 1.5, ABSI tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Absci Corporation and its sector.